Blog‎ > ‎

Corneal Cross-linking ... another positive step forward

posted Dec 7, 2011, 9:16 PM by Jen Weigel   [ updated Jan 7, 2012, 6:16 PM ]
There has been a lot of talk about corneal cross-linking lately in journals and in the lecture circuit.

"The use of UV-A irradiation combined with topical Riboflavin to increase collagen cross-linking (CXL) has shown great potential over this past decade in slowing or eliminating progression of keratoconus and post-LASIK ectasia," Dr. Holzman said.  Prior to cross-linking, we were pretty much limited to glasses, contacts, or PKP, but now we have a powerful treatment option for patients with these unique conditions.

In September 2011, a company called Avedro had gotten FDA orphan drug status for its cross-linking system for the treatment of keratoconus.  Yesterday, it received a second orphan drug status for its same system for the treatment of post-refractive surgery ectasia.

With so many positive changes in the development of this treatment option, cross-linking is sure to have a positive impact on the lives of many patients in your practices.  - jw
Comments